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Abstract: Sinonasal melanoma is a rare subtype of melanoma and little is known about its molecular
fingerprint. Systemic treatment options are limited, as targetable BRAF mutations are rare compared
to cutaneous melanoma. Currently, metastatic sinonasal melanoma is being treated according to the
guidelines of cutaneous melanoma. In this study, we investigated the molecular profile of 19 primary
sinonasal melanomas, using a novel customized melanoma-specific next generation sequencing
(NGS) panel (MelArray) of 190 genes. Results were correlated to histological and clinical features to
further characterize this rare, aggressive type of melanoma and screen for prognostic markers and
possible treatment options. Molecular profiles encompassed predominantly mutations in NRAS (25%),
whereas KIT or BRAF p.V600 mutations were not detected. Tumor mutational burden was overall low.
High level of copy number variations (CNVs) were associated with alterations in DNA-repair genes
and shorter distant metastasis-free survival (p = 0.005). Monomorphic (vs. pleomorphic) morphology
was found to be significantly associated with worse disease-specific survival (p < 0.001), however no
correlation between morphology and molecular aberrations was found. A variety of alterations in
different pathways were detected, justifying molecular testing and opening potential personalized
treatment options in current study or compassionate use settings.
Keywords: sinonasal melanoma; next generation sequencing; mutations; morpho-molecular
assessment; personalized therapy
1. Introduction
Sinonasal melanoma is a rare subtype of melanoma (<1% of all melanomas). While cutaneous
melanoma meanwhile has a reasonably characterized mutational profile and various treatment options
exist, little is known about sinonasal melanoma. Cutaneous melanoma can be divided into molecular
subgroups (BRAF mutated, NRAS mutated, NF1 mutated, triple wild-type) and show the typical ultra
violet (UV) signature (C > T transition). Several studies have aimed to investigate the mutational
profile of sinonasal melanoma. However, most of them are limited to the most commonly known
mutated genes in melanoma. Schoenewolf et al. look at KIT only, known to be typically altered in
mucosal melanoma, and shown to be negatively correlated to immunohistochemical expression [1];
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and find one out of 19 tumors to be mutated with strong immunohistochemical staining in up to 25% of
the tumor cells. The mutation, however, is synonymous [2]. Other PCR- and Sanger sequencing-based
studies find either no or only a low amount of BRAF-mutated sinonasal melanoma, few KIT mutations,
and several NRAS mutations [3–6]. Further investigations include the TERT promoter region, which is
found to be mutated in 7–8% of sinonasal melanoma, while a known single nucleotide polymorphism
(SNP) is found in 82% [7,8]. Only few published studies use a next generation sequencing (NGS)
approach, one of them using a 50 gene melanoma panel. Out of 66 patients, 27 patients show one or
more mutations, among them, mostly NRAS (30%), BRAF (7.5%), and KIT (4.5%). Only one patient
has multiple alterations in TP53, KIT, NOTCH1, PIK3R1, and ERBB2 [9]. Additionally, some of the
studies search for gene copy number alterations and find RREB1 and MYB to be lost or CCND1 to be
amplified [4,5]. Another group looks at 29 genes and finds alterations in mainly NRAS or KRAS, but
no KIT mutation [10]. The most recent study analyzes a large cohort of 95 sinonasal melanomas [11].
However, only BRAF, NRAS, KIT and SF3B1 are investigated by Sanger sequencing.
Despite various treatment options for cutaneous melanoma patients, including local and systemic
therapies, using targeted or immunotherapeutic agents [12], options for sinonasal melanoma patients
are limited. Primary tumors and localized disease are typically treated with surgery and adjuvant
radiotherapy [13]. Nowadays, surgery consists of a transnasal endoscopic resection with intraoperative
navigation as requested (Figure 1a).
In the metastatic and advanced disease setting, mucosal melanomas are treated according to
guidelines for cutaneous melanoma [14]. However, outcome data on systemic treatment are very
limited, as mucosal location is often an exclusion criterion in melanoma clinical trials [15]. Furthermore,
the disease is comparably rare and immunotherapy studies that did not exclude mucosal melanoma
were unable to perform subgroup analyses.
Besides immunotherapy, targeted therapy using specific inhibitors is an option [15]. However, also
here, data are limited, partly because targetable mutations in sinonasal melanoma are rare and largely
uninvestigated. Some of them showed KIT mutations, enabling treatment with imatinib or nilotinib [15].
Others carry NRAS mutations, offering the opportunity to use Mitogen-activated protein kinase kinase
(MEK) inhibitors [15]. Currently, several ongoing clinical trials evaluate different treatments in mucosal
melanoma patients, e.g., ipilimumab/nivolumab combination, or IL2/pembrolizumab combination
(NCT03241186, NCT02748564).
In this study, we performed molecular profiling of a cohort of sinonasal primary melanomas using
a targeted next generation sequencing (NGS) approach. In addition, we characterized the tumors
according to their histological and immunological features. The aim of this study was to further
investigate molecular alterations as well as morphological properties and immunogenicity of this rare
subtype of melanoma and thereby screen for prognostic markers and possible therapeutic targets.
2. Results
2.1. Mutation Analysis Reveals a Generally Low Mutational Burden with NRAS Mutation as the Most
Frequent Driver
Mutational profiling of 190 genes revealed a low number of mutations in most of the primary
sinonasal melanoma samples. MelArray mutational burden reached from 0.7 to 32.9 non-synonymous
mutations/Mb (Figure 1b, upper part, light blue) and few synonymous mutations ranging from 0
to 4 mutations/Mb (Figure 1b, upper part, dark blue). Eighteen of 19 patients had a mutational
burden ranging from zero to four non-synonymous coding mutations; whereas, one patient had a high
mutational burden with 24 non-synonymous coding mutations.
While NRAS was most frequently mutated in our cohort (26%, five patients), other genes were
mutated in only one or two patients, illustrating the heterogeneous mutational profile of sinonasal
melanoma (Figure 1b, lower part). One of the NRAS mutated patients had a (non-canonical) BRAF
mutation in addition. Two patients had a NF1 mutation, while all the other 13 patients were triple
wild-type according to the molecular classification of melanoma [16]. This result was significantly
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different to TCGA data of cutaneous melanoma, where BRAF mutations are the most frequent driver
(Figure 1c). One patient had a KRAS mutation, most likely being the oncogenic driver of the disease.
The patient with the high mutational burden had a RASopathy profile, showing a NF1 mutation,
together with truncation of RASA2, leading to increased activation of Ras [17]. By retrieving the
COSMIC (Catalogue Of Somatic Mutations In Cancer) mutational signature from this patient, we
found closest similarities with signature 1 and partially signature 15 (Appendix A Figure A1). The
detected GNAQ mutation (p.Thr54Met) is a variant of unknown significance and is neither reported in
the ClinVar database nor found in the TCGA cutaneous or uveal melanoma cohort. Another patient
had a subclonal activating PIK3CA mutation. No patient had mutations in KIT. Two patients showed
TERT promoter mutations, with one being a so far unknown mutation.
We analyzed the clinical data of patients with and without driver mutations and did not find any
significant correlation with local recurrence rates or survival (Log-rank test, p = 0.125 and p = 0.776).
However, patients with NRAS mutations showed a trend towards prolonged distant metastasis-free
survival (Figure 1d) (Log-rank test, p = 0.06), but no difference in disease specific survival (Figure 1e, p
= 0.9), while the two groups (NRAS mutant vs. NRAS wild-type) showed equal distribution of age,
sex, and TNM stage.
Furthermore, we analyzed our data for UV signature mutations (mostly C > T transition) and
found a generally lower number of C > T transitions compared to published data for cutaneous
melanoma. All samples had C > T transitions below 75%, which was the median percentage found in
the TCGA for cutaneous melanoma. Seven samples had more than 60% C > T (Figure 1f).
2.2. Presence or Absence of DNA Repair Gene Alterations Divide the Cohort into Different Groups
Genome-wide assessment of copy number alterations in our cohort of sinonasal melanoma
revealed amplifications of parts of chromosomes 1, 6, 8, and 12 and partial losses of chromosomes
6, 8, 10, 14, and 17 (Figure 2a). Furthermore, we detected two different groups (Figure 2b), one with
alterations in DNA repair genes, and one without. By looking into further differences between those
two groups, it was evident that the group with copy number variations (CNVs) in DNA repair genes
had a generally high amount of CNVs (>1400; hereafter named CNVhigh), while the other group had
only few CNVs (<850; hereafter named CNVlow) (Figure 2c). All of the CNVhigh patients had partial or
heterozygous loss of one or more genes involved in DNA repair, such as ATM, MLH3, BRCA1/2, PMS2
or amplification of PARP. In contrast, all but one patient of the CNVlow group had no changes in copy
numbers of DNA repair genes, except for a patient with a PMS2 amplification (Figure 2b).
2.3. Low CNV Numbers Are Associated with NRAS Mutations and Prolonged Distant Metastasis-Free
Survival
Interestingly, all patients with NRAS mutations (Figure 2b, grey) had low levels of CNVs and
no alterations in DNA repair genes, except for the patient with the BRAF/NRAS double mutation
(Figure 2b, purple), who had a high number of CNVs and various alterations in DNA repair genes.
Furthermore, while all NRAS mutant patients (Figure 2d, grey) had either no alteration or only an
amplification in the 190 MelArray genes, the BRAF/NRAS mutated patient (Figure 2d, purple) showed
numerous deletions as well. Correlation with clinical data revealed a prolonged distant metastasis-free
survival of patients in the CNVlow group (Figure 2e; p = 0.005). There was no difference in overall
survival (Figure 2f; p = 0.148).
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Figure 1. Mutational landscape of sinonasal melanoma. (a) Upper panels: Endoscopic photography 
of a sinonasal melanoma. The dark discoloration of the nasal mucosa with irregular margins is easily 
recognizable. * Inferior turbinate, ** middle turbinate, # nasal floor, + nasal septum. Lower panels: 
Surgical specimen after endoscopic removal of sinonasal melanomas. The dark areas of sinonasal 
melanoma have been excised with sufficient margins of normal mucosa around it. (b) Upper part: 
Analysis of mutational burden with non-synonymous (light blue) and synonymous (dark blue) 
mutations. Lower part: mutational landscape of the primary sinonasal melanoma cohort. (c) 
Comparison of frequencies of the four molecular subgroups in between cutaneous melanoma (from 
TCGA) and our primary sinonasal melanoma cohort. (d) Survival curve showing distant metastasis-
Figure 1. Mutation l landscape of sinonasal melanoma. (a) Upper : Endoscopic ph tography
of a sinonasal melanoma. The dark isc loration of the nasal mucosa with irregular margins is
easily recognizable. * Inferior turbinate, ** middle turbinate, # nasal floor, + nasal septum. Lower
panels: Surgical specimen after endoscopic removal of sinonasal melanomas. The dark areas of
sinonasal melanoma have been excised with sufficient margins of normal mucosa around it. (b) Upper
part: Analysis of mutational burden with non-synonymous (light blue) and synonymous (dark
blue) mutations. Lower part: mutational landscape of the primary sinonasal melanoma cohort.
(c) Comparison of frequencies of the four molecular subgroups in between cutaneous melanoma
(from TCGA) and our primary sinonasal melanoma cohort. (d) Survival curve showing distant
metastasis-free survival in NRAS wild-type (WT) (red) and NRAS mutated (blue) patients. (e) Survival
curve showing disease-specific survival in NRAS WT (red) and NRAS mutated (blue) patients.
(f) Transition/Transversion plot of the sinonasal melanoma cohort.
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Figure 2. Genome-wide copy number assessment of the primary sinonasal melanoma cohort. (a) 
Global copy number gains (red) and losses (blue). (b) Copy number alterations in DNA repair genes. 
Grey boxes: NRAS mutant patients, purple box: BRAF/NRAS double mutated patient. (c) Amount of 
copy number variations (CNVs) across the cohort. Red bar: 1000 CNVs. (d) Copy number alterations 
in the most frequently altered MelArray genes. Grey boxes: NRAS mutant patients, purple box: 
BRAF/NRAS double mutated patient. Red: amplifications, light blue: partial deletions, dark blue: 
heterozygous deletions. (e) Survival curve showing distant metastasis-free survival in CNVhigh (blue) 
and CNVlow (red) patients. (f) Survival curve showing disease-specific survival in CNVhigh (blue) and 
CNVlow (red) patients. 
2.4. Fusions 
Investigation of 28 canonical fusion breakpoints in ALK, BRAF, MAP3K8, MET, NTRK1, 
PRKAR1A, RAF1, RET, and ROS1 did not reveal any fusion events in our cohort. 
2.5. Oncogenic Alterations Are Mostly Associated with MAPK or PI3K/mTOR Pathway 
Overall, we could identify molecular alterations that may contribute to tumorigenesis in most of 
the samples. These alterations were mainly associated with activation of MAPK and PI3K/mTOR 
signaling pathways. Furthermore, alterations affecting cell cycle and DNA repair were evident (Table 1). 
  
Figure 2. eno e-wide copy number assessment of the primary sinonasal melanoma cohort. (a) Global
copy number gains (red) and losse (blue). (b) Copy nu lterations in DNA repair genes. Grey
boxes: NRAS mutant patients, purple box: BR ouble mu ated patient. (c) Amount of copy
number variations (CNVs) across the cohort. Red bar: Vs. (d) Copy number alterations in the
most frequently altered MelArray genes. Grey boxes: NRAS mutant patients, purple box: BRAF/NRAS
double mutated patient. Red: amplifications, light blue: partial deletions, dark blue: heterozygous
deletions. (e) Survival curve showing distant metastasis-free survival in CNVhigh (blue) and CNVlow
(red) patients. (f) Survival curve showing disease-specific survival in CNVhigh (blue) and CNVlow
(red) patients.
2.4. Fusions
Investigation of 28 canonical fusion breakpoints in ALK, BRAF, MAP3K8, MET, NTRK1, PRKAR1A,
RAF1, RET, and ROS1 did not reveal any fusion events in our cohort.
2.5. Oncogenic Alterations Are Mostly Associated with MAPK or PI3K/mTOR Pathway
Overall, we could identify molecular alterations that may contribute to tumorigenesis in most
of the samples. These alterations were mainly associat d with activation of MAPK and PI3K/mTOR
signaling pathways. Furthermore, alterations affecting cell cycle and DNA repair were evident (Table 1).
2.6. Histological Evaluation Shows an Association of Monomorphic Features with Worse Outcome
Besides molecular profiling, all tumors were analyzed according to morphology (monomorphic vs.
pleomorphic), presence of apoptosis, and presence of pigmentation. There was no correlation of these
features with either mutation or CN status. However, prolonged disease-specific survival was clearly
associated with a pleomorphic morphology (Log-rank test, p < 0.001) (Figure 3a,b). Furthermore,
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all patients who received palliative care at first presentation turned out to have melanomas with
monomorphic appearance. The only patient who received curative treatment died within six months
after diagnosis; whereas, all other patients in the curative arm had a pleomorphic morphology and
had a longer disease-specific survival. There was no significant difference in sex or age of the patients
in the two groups (Log-rank test, p > 0.05).
Table 1. Main molecular alterations and affected pathways.
Sample Alteration Pathway/Function
SM2 KRAS amplification, NF1/PTEN/CDKN2A loss MAPK pathway, PI3K/mTOR pathway, cell cycle
SM3 TP53 loss Tumor suppressor
SM4 TP53 p.Arg273Cys (subclonal) Tumor suppressor
SM5 PTEN p.Leu108Arg PI3K/mTOR pathway
SM6 MAP3K5 p.Gly39AlafsTer142 (subclonal),MAP3K5/PTEN/CDKN2A loss p38 pathway, PI3K/mTOR pathway, cell cycle
SM7 NRAS p.Gln61His MAPK pathway
SM8 NRAS p.Gly61Lys MAPK pathway
SM9 BRAF p.Asp594Asn, NRAS p.Gly12Asp,TP53/CDKN2A loss MAPK pathway, pathway cell cycle
SM10 - -
SM11 - -
SM12 NRAS p.Gln61Lys, TERT prom. -124C>T MAPK pathway
SM13 NF1 p.Leu307Ter MAPK pathway
SM14 MAP3K5 p.Pro47ValfsTer56, MAP3K5p.Gly39AlafsTer142 (both subclonal) p38 pathway
SM15 PTEN p.Arg74Ile (subclonal) PI3K/mTOR pathway
SM16 KRAS p.Gly12Ala, KRAS amplification, PTENloss MAPK pathway, PI3K/mTOR pathway
SM17 NF1 p.Gln1520Ter, NF1 loss, BRCA1 loss, BRCA1predictive damaging VUS MAPK pathway, DNA repair
SM18 - -
SM19 PIK3CA p.Glu545Gly PI3K/mTOR pathway
SM20 NRAS p.Gln61Arg MAPK pathway
Only one of the monomorphic melanoma tumors was pigmented. Presence or absence of apoptosis
or pigmentation had no impact on clinical properties. However, amelanotic melanoma were more
common in older patients (Mann Whitney U, p = 0.003). Amelanotic tumors were confirmed to be
melanoma by immunohistochemical positivity of S100, HMB-45, and MelanA (Table 2). The median
age of patients with pigmented melanoma was 63.0 years (interquartile range (IQR) 46–67); whereas,
the mean age of patients with amelanotic melanoma was 79.5 years (IQR 69.25–89.25) (Figure 3c,d).
Table 2. Immunohistochemical staining of melanocytic markers. The staining was rated as “+”
(positive), “(+)” (partially positive), “−” (negative) or “N/D” (not determined).
Sample Pigmentation Status S100 HMB-45 MelanA SOX10
SM2 pigmented + N/D + N/D
SM3 amelanotic + N/D + N/D
SM4 amelanotic (+) + + N/D
SM5 amelanotic + N/D + N/D
SM6 pigmented + N/D + N/D
SM7 amelanotic + (+) + N/D
SM8 amelanotic + (+) + N/D
SM9 amelanotic + (+) + N/D
SM10 amelanotic + + + N/D
SM11 amelanotic − + (+) +
SM12 pigmented + N/D + N/D
SM13 pigmented + + + N/D
SM14 amelanotic + + + N/D
SM15 amelanotic + + + N/D
SM16 amelanotic (+) + (+) +
SM17 amelanotic + + + N/D
SM18 amelanotic + + + N/D
SM19 pigmented + + + N/D
SM20 pigmented + + + N/D
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Figure 3. Histological characteristics of the primary sinonasal melanoma cohort. (a) hematoxylin and
eosin (H and E) staining of a representative case of primary sinonasal melanoma with monomorphic
(left) and pleomorphic (right) histology. (b) Survival curve showing disease-specific survival in patients
with monomorphic (red) and pleomorphic (blue) histology. (c) H and E staining of a representative
case of monomorphic amelanotic tumor (upper left), monomorphic pigmented tumor (upp r right),
pleomorp ic amelanotic tumor (lower left), and pleomorphic pigmented tumor (lower right). (d) Graph
showing an association of tumor pigmentation and age. Data are displayed with median. ** p < 0.01.
Scale bar in all panels 100 µm.
2.7. Immunohistochemistry Reveals Mostly PD-L1 Negativity and Infiltration of T-Cells
All primary tumors were stained for PD-L1, CD4 and CD8 to assess PD-L1 status and T-cell
infiltration. Most of the tumors were negative for PD-L1, whereas most patients had some positivity for
PD-L1 in immune cells. Only one tumor exhibited strong staining, while three others showed a weak
to intermediate staining. The patient with the high mutational burden showed no PD-L1 expression in
the tumor, but intermediate expression in the immune cells. Most of the tumors had intermediate to
strong infiltration of CD4+ and CD8+ cells. Three tumors did not show any T-cell infiltration or PD-L1
staining of immune cells and tumor. These factors did not show any correlation with oncological
outcome measures.
2.8. Immunotherapy is an Option for Sinonasal Melanoma Patients
Current treatment options are rare as there are no targeted therapies for sinonasal melanoma.
While patients with systemic disease were treated with chemotherapy or sorafenib in the past, today,
immunotherapy is an option. Three patients of our cohort received immunotherapy, with either
nivolumab or pembrolizumab monotherapy or a combination of ipilimumab and nivolumab. While
one patient receiving ipilimumab/nivolumab combo responded, treatment had to be stopped due
to side effects. The other patient treated with the combination therapy received four cycles of the
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combination and proceeded with 21 cycles of nivolumab monotherapy. Both patients responded to
treatment. The patient treated with pembrolizumab did not respond. Interestingly, the two responding
patients in our cohort were negative for PD-L1 in the tumor (TC0), while the non-responder showed
some expression (i.e., TC1). Furthermore, responding patients had a low PD-L1 score in the immune
cells (IC0 or IC1), whereas the non-responder had an IC3 (Figure 4). All three patients had low levels of
CD4 infiltration and low or high CD8 infiltration. There was no difference in TMB between responders
and the non-responder. While the non-responder had high CNV numbers (2049 CNVs), the responders
had either high (3120 CNVs) or low CNV (849 CNVs) numbers. However, the small sample size and
different treatment regimens do not allow for proper statistical analysis.
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After progression under approved therapies, there may be options to include patients into 
clinical studies or compassionate use programs due to their molecular alterations. In our cohort, we 
detected several alterations that may allow treatment apart from approved therapies. Patients with 
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Figure 4. FDG-PET/CT and immunohistochemical characteristics of non-responder and responder
with sinonasal melanoma to immunotherapy. (a) FDG-PET/CT scan of a sinonasal melanoma
patient, progressing under immunotherapy (left: before treatment; right: progression). (b)
Immunohistochemical expression of PD-L1 in the tumor (upper panel), and in the immune cells
(lower left), the latter c rresponding to CD4 positive cells in the s me region (lower right). (c)
FDG-PET/CT scan of a si onasal melanoma patient, resp nding to immu otherapy (left: before
treatment; right: complete response). (d) No recognizable immunohistochemical expression of PD-L1
in the tumor cells (upper panel), and virtually absent PD-L1 expression in the immune cells (lower left),
the latter corresponding to CD4 positive cells in the same region (lower right). Scale bar in all histology
panels 50 µm.
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2.9. Molecular Alterations Provide Opportunities to Experimental Therapy
After progression under approved therapies, there may be options to include patients into
clinical studies or compassionate use programs due to their molecular alterations. In our cohort, we
detected several alterations that may allow treatment apart from approved therapies. Patients with
alterations in NF1 could be included into clinical trials investigating the effect of the MEK inhibitor
cobimetinib (NCT02639546), the mTOR inhibitor temsirolimus (e.g., NCT03297606), a SHP-2 inhibitor
(NCT03634982) or the pan-RAF inhibitor LXH254 (NCT02607813). Alterations in PIK3CA or PTEN
allow inclusion into clinical trials with mTOR inhibitors everolimus or temsirolimus (NCT02029001,
NCT03297606). Furthermore, patients with PIK3CA alteration can be included into studies investigating
PI3K inhibitors (e.g., NCT03006172) and patients with PTEN alterations could be treated with the AKT
inhibitor ipataserib in combination with atezolizumab in clinical trials (NCT03673787). Other trials are
investigating the effect of the CDK4/6 inhibitor palbociclib in patients with CDKN2A alterations (e.g.,
NCT02693535, NCT03297606). Loss of BRCA1 is an inclusion criterion for clinical trials evaluating the
effect of a PARP inhibitor in combination with immunotherapy (e.g., NCT03330405, NCT02660034).
3. Discussion
Our finding of low mutational burden in sinonasal melanoma is consistent with published data
about mucosal melanoma that had a mean mutational burden of 2.64 mutations/Mb ranging from
0.54–15.25 mutations/Mb [18] and showed a significant difference to cutaneous melanoma that usually
have a very high mutational burden [19,20].
While cutaneous melanoma can be divided into four molecular subgroups (BRAF-, NRAS-, NF1-
mutated or triple WT) [19], our cohort of sinonasal melanoma did not show such distribution. However,
the frequency of NRAS mutations seemed to be similar in cutaneous and sinonasal melanoma (26%
this study vs. 28% TCGA vs. 26% Hodis et al.) [19,20]. Other mutations known from cutaneous
melanoma were rare, which is in line with previous reports [6,9]. As also reported previously, the
BRAF mutation was not a p.V600 hotspot mutation [4,5]. Mutations in KIT, which are commonly
found in acral melanoma and mucosal melanoma of other localizations [18,21], were not present in our
cohort of sinonasal melanoma. The presence of KIT mutations is controversially reported, as there are
both observations of low frequency and an absence of KIT mutations in sinonasal melanoma [4–7,9,22].
Furthermore, only one subclonal variant of unknown significance in GNAQ and no GNA11 mutations,
usually present in uveal melanoma, were found [23]. Interestingly, one patient showed a RASopathy
profile with NF1 truncation and mutations in RASopathy genes like RASA1 and RASA2, which is
known from cutaneous melanoma [17]. To the best of our knowledge, this profile has not yet been
described in sinonasal melanoma. NF1 mutated melanoma was previously associated with a higher
mutational burden and elevated C>T transition [24]. Canonical TERT promoter mutations were
previously found in 8% of sinonasal melanoma, with 82% of tumors having –245G>A SNPs [8]. Our
cohort had one patient with a canonical –124C>T mutation and one patient with a –185C>G mutation,
which was previously unknown. SF3B1 mutations, reported at low frequencies in other cohorts [11],
were not present in our cohort. A study from Cosgarea et al. investigate mucosal melanomas using a
NGS panel including 15 head and neck primary tumors. However, the exact location of those head
and neck mucosal melanomas are not further specified, so probably sites other than sinonasal tract
have been included (e.g., oral cavity). Nevertheless, they find similar results with NRAS mutations as
the most frequent driver and no evidence of KIT mutations [10].
For cutaneous melanoma, it was previously shown that NRAS mutations are associated with
shorter distant metastasis-free survival compared to BRAF mutated patients, but there is no difference
between NRAS mutated and BRAF/NRAS WT patients [25]. Likewise, we did not find differences
in overall survival between NRAS mutant and wild-type patients, but a trend towards longer
distant metastasis-free survival in NRAS mutated patients. Amit et al. reported no association of
NRAS mutation and disease-free survival or distant-metastasis free survival (p = 0.31 and 0.57) [9].
Furthermore, in cutaneous melanoma, a correlation of NRAS mutation and higher age was found [26].
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By analyzing UV signature mutations, we found both samples with low C>T transition and
samples with higher C>T transition. However, all samples were below the median percentage of 75%
C>T transition found for cutaneous melanoma in the TCGA [19]. Actually, 76% of primary tumors
and 84% of metastatic samples had UV signatures in the TCGA; whereas, only 36% of our sinonasal
melanomas had a C>T transition above 60%. Previously published data about mucosal melanoma
(including sinonasal) showed 60% UV signature in mucosal melanoma compared to 70% in cutaneous
melanoma [22].
Investigation of copy number changes revealed a high amount of CNVs in a number of samples,
which fits to a finding by Curtin et al., who report a higher degree of copy number alterations in acral
and mucosal melanoma compared to cutaneous ones [27]. By comparing chromosomal aberrations,
we found similar alterations, e.g., gains of chromosome 1q, 6p, 17q or losses of chromosome 8p, 10,
and 11p. Likewise, a study on 14 sinonasal melanoma that were investigated by CGH array, finds
gains of chromosome 1q, 6p, and 8q, similar to our results [28]. However, approximately half of our
samples had a low number of CNVs and survival analysis showed a prolonged distant metastasis-free
survival in CNVlow patients, which was, to our knowledge, not yet reported elsewhere.
Loss of MYB was found in four of our cases. Previously, such a loss was observed by MYB FISH [4].
Furthermore, they show a loss of PTEN and CDKN2A (p16) protein by using immunohistochemistry.
Accordingly, four of our samples had a loss of PTEN and/or CDKN2A, respectively. While Chraybi et
al. found CCND1 amplifications in several cases [5], our results showed only one case with a loss and
one case with an amplification.
Fusion events in melanoma are rare and sometimes result in drug resistance [29]. Usually they
occur in tumors without driver mutations [30]. We investigated 28 canonical fusion breakpoints in
seven genes known from rearrangements in melanoma. However, we did not detect any gene fusions.
While specific mutations do not seem to affect the outcome of the disease, these alterations could
serve as potential targets for systemic therapy in metastatic sinonasal melanoma. The BRAF/MEK
inhibitor combination is already approved for melanoma with BRAF mutation. Other inhibitors
could be made available via clinical studies or compassionate use programs. Patients with defects
in the DNA repair machinery may respond to PARP inhibitor treatment, as previously shown for
prostate cancer patients [31]. NF1 mutated melanomas may respond to MEK inhibitor treatment as
suggested by preclinical studies and a case report [32]. A clinical trial will investigate the effect of
everolimus, sorafenib or trametinib in NF1-mutated melanoma (NCT02645149). In the NCI-MATCH
trial, patients with NF1 mutations are treated with trametinib. However, no results have been published
yet, as completion of the trials is expected for mid-2022. Furthermore, clinical trials are investigating
the impact of CDK4/6 inhibitors in patients with CDKN2A loss and the impact of mTOR inhibitors
on patients with PIK3CA or PTEN alterations (NCT02645149, NCT03297606). However, due to the
very low incidence of sinonasal melanoma, there are no specific clinical studies or case reports on
such experimental therapies. Mutational profiling in sinonasal melanoma patients will identify the
above-mentioned targets and may allow inclusion of patients into trials for solid tumors.
To our knowledge, an association of pleomorphic morphology and prolonged disease specific
survival compared to tumors with monomorphic histology, as found here, is not reported elsewhere.
Similar to Amit et al., we did not find any association of morphology and mutation status [9]. We
saw amelanotic tumors being associated with higher age of the patients, but we did not observe a
correlation with pigmentation and survival, even though only one of the monomorphic melanomas
was pigmented. These results contradict a study, that shows an amelanotic subtype of sinonasal
melanoma is associated with worse outcome [33], however, the study cohort is all Chinese patients,
and therefore a different ethnic background from our samples. For cutaneous melanoma, a large cohort
is analyzed and a poor survival of amelanotic melanoma is shown compared to pigmented tumors [34].
PD-L1 staining of the primary sinonasal melanomas revealed a negative result in most patients,
which is in line with published data about mucosal melanoma that shows significantly less PD-L1
expression compared to cutaneous melanoma [22]. However, the relevance of PD-L1 expression in
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melanoma is not that clear, as the combination of ipilimumab and nivolumab was shown to be effective
in both PD-L1 positive and negative patients [35].
Three patients showed a loss of CD274, the PD-L1 gene, with no expression of PD-L1 in the
immunohistochemical staining. Although this might lead to failure of therapeutic response, the
number of cases was too small to make further conclusions. A report in oral squamous cell carcinoma
showed that CD274-amplified tumors has a significantly higher frequency of positive PD-L1 staining
than cases without amplification [36].
4. Materials and Methods
4.1. Patient Samples
We included 19 patients who were diagnosed and treated at the University Hospital Zurich from
2006–2018 and that had resected, primary tumors available. The local ethics review board approved
the study (BASEC 2016.00162, including amendment from 03.05.2018). All patients treated in 2016 and
afterwards signed written informed consent approved by the local ethics review board (EK647/800) in
addition to the general institutional consent.
4.2. Collection of Clinical Data
A retrospective chart review of all patients with sinonasal melanoma treated at the Department
for Otorhinolaryngology—Head and Neck Surgery of the University Hospital Zurich, was performed
(Table 3). We examined charts to obtain detailed demographic and clinical data (gender, age, TNM
stage, lymph node involvement, orbit and skull base invasion, treatment modalities, follow-up,
and recurrence). We included only cases with histologically and immunohistochemically verified
sinonasal melanoma in the analysis. A Swiss Medical Association board-certified head and neck
pathologist (N.J.R) reviewed all cases to ensure the accuracy of the diagnosis. Staging was performed
according to the Union International Contre le Cancer (UICC), TNM Staging for sinonasal cancer,
8th edition 2018 [37]. All patients were presented at the local multidisciplinary tumor board and
treatment recommendation was based on the available guidelines and literature at the time of the
patients’ accrual.
Table 3. Description of the sinonasal melanoma patient cohort.
Characteristics Distribution in the cohort
Gender n (%)
Male 8 (42%)
Female 11 (58%)
Age at diagnosis Median (range)
Male 72 (53–84)
Female 71 (49–84)
Total 71 (43–84)
Clinical classification of the tumor n (%)
T3 11 (58%)
T4 8 (42%)
Pigmentation status of primary tumor n (%)
Pigmented 6 (32%)
Amelanotic 13 (68%)
Morphology of primary tumor n (%)
Monomorphic 6 (32%)
Pleomorphic 13 (68%)
Cancers 2019, 11, 1329 13 of 17
4.3. Sample Preparation
Patient material was obtained from formalin-fixed paraffin-embedded (FFPE) tissue. One 2 µm
section was stained with hematoxylin and eosin (H and E) and a pathologist (N.J.R.) marked the
tumor area as well as regions of normal tissue. Punch biopsies of 0.4 mm in diameter were taken from
both areas.
4.4. DNA Isolation
DNA of normal and tumor tissue was isolated using the Maxwell 16 FFPE Tissue LEV DNA
Purification Kit (Promega, Madison, WI, USA) and quantified using a fluorometric assay (Qubit,
Thermo Fisher Scientific, Waltham, MA, USA).
4.5. Library Preparation
The KAPA HyperPlus Kit was used to fragment the DNA and build sequencing libraries. Unique
sequencing adapters were ligated to the libraries to allow pooling of up to 12 libraries for target capture,
which was performed using a customized probe set [38] (manuscript submitted) by Roche NimbleGen
(Basel, Switzerland).
4.6. Sequencing
Of the samples, 16–18 were sequenced paired-end (150 bp) on one lane of a HiSeq4000 Illumina
machine (Illumina, San Diego, CA, USA).
4.7. Analysis
A customized pipeline and open source software were used to analyze the data. After
demultiplexing, fastq files went through quality control using Picard. Read trimming was performed
using skewer [39] and bwa (Burrows-Wheeler Aligner) alignment [40]. GATK4 and MuTect2 [41] were
used for generation of vcf files. CNV analysis was done using Sequenza to derive logR values [42].
4.8. (Immuno-)Histological Staining and Evaluation
Formalin-fixed and paraffin-embedded (FFPE) specimens were examined on 2 µm hematoxylin
and eosin (H and E) stained sections. The Ventana Benchmark automated staining system was used
for immunohistochemical staining on 2 µm sections. For PD-L1 staining the anti-PD-L1 (E1L3N)
antibody (1:100, Cell Signaling Technology, Cambridge, United Kingdom) was used. Detection was
performed with optiView DAB-kit (Ventana). For CD4 staining a polyclonal anti-CD4 antibody
(1:100, R&D Systems, McKinley, MN USA) was used. CD8 staining was performed using a
monoclonal anti-CD8 (4B11) antibody (Bio-Rad Laboratories; 1:100). Detection was performed with
rabbit-anti-goat horseradish peroxidase. Histological features (morphology, pigmentation, apoptosis)
and immunohistochemical staining for CD4, CD8, and PD-L1 were evaluated by an experienced head
and neck pathologist (N.J.R.). PD-L1 staining was scored according to the scheme established for lung
cancer [43]: tumor cells: TC0 = negative, TC1 = 1–5%, TC2 = 5–50%, TC3 ≥ 50%; immune cells: IC0 =
negative, IC1 = 1–5%, IC2 = 5–10%, IC3 ≥ 10%. Staining of melanocytic markers was performed as
described previously [44].
4.9. Statistics
For continuous variables, median, interquartile range (IQR), or standard deviation (SD) were
given. To compare the distribution among samples, the non-parametric Mann Whitney U test was
used for two samples. Binary variables were associated in contingency tables using the two-tailed
Fisher exact test. Survival curves were plotted according to Kaplan–Meier and the Log-rank test was
used to compare factors. A p-value lower than 0.05 was considered to indicate statistical significance.
Statistical analyses were performed using SPSS® 25.0.0.0 software (IBM®, Armonk, NY, USA).
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5. Conclusions
This study shows the importance of molecular profiling in sinonasal melanoma as it revealed
possible clinical trial opportunities and compassionate use programs for these patients with limited
treatment options. Furthermore, it has prognostic value, as, high number of CNV load is associated
with reduced distant metastasis-free survival, whereas NRAS mutations are associated with a low
CNV load. Notably, KIT mutations were absent from our cohort. Additionally, a monomorphic
histology was associated with worse outcome of the disease (Table 4), which supports the notion that a
combination of next generation sequencing data and immunohistochemistry are important tools for
clinical decision support for sinonasal melanomas.
Table 4. Overview of major findings.
Distant Metastasis-Free Survival Disease-Specific Survival
Median (SE) p-Value Median (SE) p-Value
NRAS Status
WT 13.1
0.049
19.0 (10.7)
0.921Mutated 60.0 13.0 (20.5)
CNV Status
CNVhigh -(-)
0.005
13.0 (1.6)
0.148
CNVlow 6.0 (1.3) 45.0 (17.95)
Morphology
Monomorphic 5.0 (-)
0.941
4.0 (2.0)
0.000082Pleomorphic 13.0 (2.6) 45.0 (17.95)
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